StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
34
This month
1
This year
3
Publishing Date
2024 - 04 - 08
1
2024 - 02 - 07
1
2024 - 01 - 23
1
2023 - 12 - 18
1
2023 - 12 - 13
1
2023 - 11 - 21
1
2023 - 10 - 21
1
2023 - 10 - 03
1
2023 - 06 - 19
1
2023 - 03 - 03
1
2023 - 01 - 26
1
2022 - 11 - 30
1
2022 - 11 - 14
1
2022 - 06 - 06
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 01
1
2022 - 03 - 16
2
2022 - 03 - 01
2
2021 - 09 - 28
1
2021 - 09 - 27
2
2021 - 08 - 31
1
2021 - 08 - 05
1
2021 - 06 - 07
2
2021 - 05 - 21
2
2021 - 04 - 13
1
2021 - 04 - 11
1
2021 - 03 - 29
1
2021 - 03 - 17
1
Sector
Commercial services
1
Health technology
34
Tags
Aci-24
1
Aci-24.060
1
Active
1
Alliances
2
Alzheimer
1
Alzheimer's
2
Alzheimer's disease
1
Alzheimer’s
2
Anti-amyloid beta
1
Antibody
1
Asia
1
Aspen-06
1
Association
1
Authorization
2
Biomidwest
1
Biopharma
1
Biotech
3
Breast
1
Cancer
12
Cel
2
Cell
1
Ceo
1
China
1
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
3
Colorectal cancer
1
Congress
1
Covid
4
Covid-19
2
Designation
2
Disease
3
Ema
2
Emergency use authorization
2
Fda
4
Gastrointestinal
1
Growth
3
Heart
6
Iot
3
Kidney
2
Lung cancer
2
Market
3
N/a
22
Phase 2
3
Phase 2b
2
Phase 3
3
Pos
2
Positive
30
Presentation
2
Research
2
Results
8
Retevmo
2
Risk
2
Sabizabulin
3
Study
5
Technology
3
Therapeutics
2
Therapy
2
Topline
6
Treatment
5
Trial
15
Entities
Ac immune sa
2
Akouos, inc.
1
Alnylam pharmaceuticals, inc.
1
Alx oncology holdings inc.
1
Beigene, ltd.
1
Eli lilly and company
34
Galapagos nv
1
Glaxosmithkline plc
3
I-mab
1
Incyte corporation
4
Johnson & johnson
1
Kiniksa pharmaceuticals, ltd.
1
Lantheus holdings, inc.
1
Morphosys ag
1
Novo nordisk a/s
1
Pfizer, inc.
1
Point biopharma global inc
1
Rigel pharmaceuticals, inc.
1
Sanofi
5
Veru inc.
3
Vir biotechnology, inc.
3
Symbols
ABBV
32
ADIL
10
ALNY
19
ALPMF
16
ALPMY
16
AMGN
17
ANVS
10
AQST
18
ARVL
33
AUY
10
AZN
18
BBIO
16
BGNE
21
BIIB
13
BMY
33
BNTX
18
BYSI
11
CHRS
24
CLDX
10
CLSD
15
DARE
13
FNCTF
40
GILD
14
GSK
13
HOTH
14
IMMP
13
IMMX
11
INCY
17
IONS
21
IT
31
JNJ
55
LLY
34
LTUM
18
MDWD
11
MRK
21
MS
12
NDAQ
87
NVS
25
NVSEF
21
PDSB
12
PFE
46
PPRUF
13
PPRUY
13
PSN
14
RCKT
11
REGN
26
RGNX
17
SCYX
11
SGEN
13
SLS
11
SNY
114
SNYNF
90
SRNE
22
TAK
15
TAYD
17
TEVJF
14
TNXP
12
VIRX
14
VRTX
11
ZLAB
11
Exchanges
Nasdaq
20
Nyse
34
Crawled Date
2024 - 04 - 08
1
2024 - 02 - 07
1
2024 - 01 - 23
1
2023 - 12 - 18
1
2023 - 12 - 13
1
2023 - 11 - 21
1
2023 - 10 - 21
1
2023 - 10 - 03
1
2023 - 06 - 19
1
2023 - 03 - 03
1
2023 - 01 - 26
1
2022 - 12 - 01
1
2022 - 11 - 14
1
2022 - 06 - 06
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 01
1
2022 - 03 - 16
2
2022 - 03 - 01
2
2021 - 09 - 28
1
2021 - 09 - 27
2
2021 - 08 - 31
1
2021 - 08 - 05
1
2021 - 06 - 07
2
2021 - 05 - 21
2
2021 - 04 - 13
1
2021 - 04 - 11
1
2021 - 03 - 29
1
2021 - 03 - 17
1
Crawled Time
00:00
3
01:00
1
02:00
1
07:00
1
10:00
1
11:00
4
12:00
2
12:15
1
12:20
1
12:30
1
13:00
1
13:20
1
14:00
3
15:00
1
16:20
1
17:00
2
18:00
1
20:00
1
20:20
1
21:00
2
22:00
3
23:00
1
Source
www.biospace.com
12
www.globenewswire.com
7
www.hutch-med.com
1
www.prnewswire.com
14
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
symbols :
Lly
save search
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published:
2024-04-08
(Crawled : 22:00)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-2.41%
|
O:
-0.3%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
-5.8%
|
O:
0.05%
H:
0.02%
C:
-2.62%
MOR
|
News
|
$18.07
0.17%
0.17%
130K
|
Health Technology
|
-0.55%
|
O:
0.06%
H:
0.22%
C:
0.0%
KNSA
|
$17.85
0.96%
0.95%
370K
|
Health Technology
|
1.02%
|
O:
0.23%
H:
1.58%
C:
0.06%
IMAB
|
$1.805
0.28%
0.28%
110K
|
Health Technology
|
0.0%
|
O:
-0.55%
H:
1.39%
C:
0.0%
GLPG
|
News
|
$28.78
-2.28%
-2.33%
140K
|
Health Technology
|
-9.7%
|
O:
0.0%
H:
0.39%
C:
-0.66%
positive
growth
market
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
Published:
2024-02-07
(Crawled : 23:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
3.85%
|
O:
0.76%
H:
4.31%
C:
2.11%
rns60
stroke
presentation
positive
topline
study
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published:
2024-01-23
(Crawled : 17:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
16.06%
|
O:
-0.51%
H:
0.37%
C:
0.32%
genetic
association
positive
research
meeting
trial
therapy
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published:
2023-12-18
(Crawled : 12:30)
- globenewswire.com
PNT
|
$13.68
2.63%
0.15%
0
|
|
-9.84%
|
O:
-10.09%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
29.07%
|
O:
1.61%
H:
1.14%
C:
0.57%
LNTH
|
$65.19
1.21%
1.2%
580K
|
Health Technology
|
-14.24%
|
O:
-19.87%
H:
5.04%
C:
-8.75%
positive
cancer
biopharma
topline
trial
results
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published:
2023-12-13
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-2.0%
|
O:
0.25%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
25.55%
|
O:
1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-1.77%
|
O:
0.0%
H:
0.0%
C:
0.0%
positive
cancer
growth
study
market
Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor
Published:
2023-11-21
(Crawled : 18:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
22.52%
|
O:
0.07%
H:
0.0%
C:
0.0%
ceo
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published:
2023-10-21
(Crawled : 16:20)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
Email alert
Add to watchlist
retevmo
lung
congress
symposium
cancer
cell
thyroid
results
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published:
2023-10-03
(Crawled : 10:00)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
36.59%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALXO
M
|
$16.24
4.77%
4.56%
440K
|
Commercial Services
|
237.21%
|
O:
68.19%
H:
2.84%
C:
-7.17%
aspen-06
positive
cancer
treatment
trial
results
Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period (2019-2032), Estimates DelveInsight
Published:
2023-06-19
(Crawled : 20:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
63.54%
|
O:
-0.41%
H:
2.02%
C:
1.37%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-9.71%
|
O:
1.71%
H:
0.0%
C:
0.0%
INCY
|
$51.72
0.14%
0.14%
1.5M
|
Health Technology
|
-18.17%
|
O:
0.3%
H:
0.17%
C:
-2.63%
positive
show
growth
study
market
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
Published:
2023-03-03
(Crawled : 21:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
Email alert
Add to watchlist
verzenio
fda
risk
breast
cancer
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
Published:
2023-01-26
(Crawled : 12:20)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
109.36%
|
O:
0.36%
H:
0.34%
C:
-0.85%
ACIU
|
$2.33
-2.1%
-2.15%
320K
|
Health Technology
|
1.28%
|
O:
10.68%
H:
0.0%
C:
-7.34%
aci-24
vaccine
trial
alzheimer’s
positive
aci-24.060
anti-amyloid beta
phase 2b
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
Published:
2022-11-30
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
97.32%
|
O:
1.0%
H:
0.11%
C:
-1.19%
disease
active
alzheimer's
positive
study
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
Published:
2022-11-14
(Crawled : 00:00)
- hutch-med.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
107.83%
|
O:
1.92%
H:
0.48%
C:
-0.84%
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-27.19%
|
O:
3.05%
H:
1.74%
C:
-0.5%
topline
china
positive
cancer
study
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 11:00)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
141.62%
|
O:
3.83%
H:
0.0%
C:
0.0%
VERU
|
$1.325
3.92%
3.77%
1.5M
|
Health Technology
|
-89.88%
|
O:
10.2%
H:
0.0%
C:
0.0%
sabizabulin
trial
presentation
positive
cancer
phase 2b
prostate cancer
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published:
2022-05-11
(Crawled : 11:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
150.82%
|
O:
-3.03%
H:
0.0%
C:
0.0%
VERU
|
$1.325
3.92%
3.77%
1.5M
|
Health Technology
|
-83.5%
|
O:
20.75%
H:
0.0%
C:
0.0%
covid-19
fda
sabizabulin
authorization
positive
phase 3
emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published:
2022-05-02
(Crawled : 13:20)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
148.79%
|
O:
-0.92%
H:
0.0%
C:
0.0%
VERU
|
$1.325
3.92%
3.77%
1.5M
|
Health Technology
|
-88.74%
|
O:
8.28%
H:
2.44%
C:
-19.07%
covid-19
fda
sabizabulin
granted
authorization
positive
phase 3
emergency use authorization
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
Published:
2022-04-01
(Crawled : 11:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
155.68%
|
O:
-0.08%
H:
2.44%
C:
2.28%
retevmo
cancer
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published:
2022-03-16
(Crawled : 17:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
165.81%
|
O:
0.87%
H:
0.27%
C:
-0.51%
pos
kidney
trial
positive results
positive
results
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Published:
2022-03-16
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
165.81%
|
O:
0.87%
H:
0.27%
C:
-0.51%
jardiance
pos
kidney
trial
disease
positive
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published:
2022-03-01
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
199.33%
|
O:
1.26%
H:
0.0%
C:
0.0%
INCY
|
$51.72
0.14%
0.14%
1.5M
|
Health Technology
|
-23.69%
|
O:
0.44%
H:
2.1%
C:
0.88%
heart
therapeutics
cel
lung cancer
positive
cancer
designation
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.